Application of the proteomic to neurological diseases;Aplicación de la proteómica a las enfermedades neurológicas

Neurologia

Volumn 22, Issue 3, 2007, Pages 170-179

  Brea, D ^a   Cristobo, I ^a   Sobrino, T ^a   Rodriguez Gonzalez R ^a   Mosquera, E ^a   Moldes, O ^a   Castillo, José ^a  

^a University Hospital of Santiago de Compostela   (Spain)

Author keywords

Neurological diseases; Proteomics; Stroke; Two dimensional electrophoresis

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; EPILEPSY; HUMAN; HUNTINGTON CHOREA; NEUROLOGIC DISEASE; PARKINSON DISEASE; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; STROKE; TWO DIMENSIONAL ELECTROPHORESIS;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CELLS, CULTURED; CEREBROVASCULAR ACCIDENT; CHROMATOGRAPHY, LIQUID; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; EPILEPSY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; HUNTINGTON DISEASE; MASS SPECTROMETRY; NERVE TISSUE PROTEINS; NERVOUS SYSTEM DISEASES; PROTEINS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SUBTRACTION TECHNIQUE;

EID: 34247525881     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science 2001;291: 1304-51.
2. Goffeau A, Barrell BG, Bussey H, Davis RW, Dujon B, Feldmann H, et al. Life with 6000 genes. Science 1996;274:563-7.
3. Waterston RH, Lindblad-Toh H, Birney E, Rogers J, Abril JF, Agarwal P, et al. Initial sequencing and comparative analysis of the mouse genome. Nature 2002;420:520-62.
4. Anderson L, Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 1997;18: 533-7.
5. Paulson L, Martin P, Persson A, Nilsson CL, Ljung E, Westman-Brinkmalm A, et al. Comparative genome- and proteome analysis of cerebral cortex from MK-801-treated rats. J Neurosci Res 2003;71:526-33.
6. Hanash S. Disease proteomics. Nature 2003;422:226-32.
7. Gagnon E, Duclos S, Rondeau C, Chevet E, Cameron PH, Steele-Mortimer O, et al. Endoplasmic reticulum-mediated phagocytosis is a mechanism of entry into macrophages. Cell 2002;110: 119-31.
8. Wasinger VC, Cordwell SJ, Cerpa-Poljak A, Yan JX, Gooley AA, Wilkins MR, et al. Progress with gene-product mapping of the Mollicutes: Mycoplasma genitalium. Electrophoresis 1995;16: 1090-4.
9. Lau AT, He QY, Chiu JF. Proteomic technology and its biomedical applications. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shangai) 2003;35:965-75.
10. O'Farrell P. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975;250:4007-21.
11. Bjellqvist B, Ek K, Righetti PG, Gianazza E, Gora A, Westermeier R, et al. Isoelectric focusing in immobilized pH gradients: principle, methodology and some applications. J Biochem Biophys Methods 1982;6:317-39
12. Göbrg A, Postel W, Gunther S. The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 1988;9:531-46.
13. Rabilloud T. A comparison between low background silver diamnimine and silver nitrate protein stains. Electrophoresis 1992;13:429-39.
14. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 1996;68:850-8.
15. Goldberg HA, Domenicucci C, Pringle GA, Sodek J. Mineral-binding proteoglycans of fetal porcine calvarial bone. J Biol Chem 1988;263:12092-101.
16. Patton WF. Detection technologies in proteome analysis. J Chromatogr B 2002;771:3-31.
17. Govorun VM, Archakov AI. Proteomic technologies in modern biomedical science. Biochemistry 2002;67:1109-23.
18. Griffiths W, Jonsson P, Liu S, Rai K, Wang Y. Electrospray and tandem mass spectrometry in biochemistry. Biochem J 2001; 355:545-61.
19. Washburn MP, Wolters D, Yates III JR. Large scale analysis of yeast proteome by multidimensional protein identification technology. Nat Biotechnol 2001;19:242-7.
20. Washburn MP, Yates J. New methods of proteome analysis: multidimensional chromatography and mass spectrometry. Proteomics: a trend guide 2000;27-30.
21. Stahl D, Lee T. Data controlled microscale liquid chromatography-tandem mass spectrometry of peptides and proteins: strategies for improved sensitivity, efficiency and effectiveness. En: James P, editor. Proteome research: mass spectrometry. Berlin: Springer, 2001; p. 55-73.
22. Gigy SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999;17:994-9.
23. Zhu H, Bilgin M, Bangham R, Hall D, Casamayor A, Bertone P, et al. Global analysis of protein activities using proteome chips. Science 2001;293:2101-5.
24. Kim SI, Voshol H, van Oostrum J, Hastings TG, Cascio M, Glucksman MJ. Neuroproteomics: expression profiling of the Brain's proteomes in health and disease. Neurochem Res 2004;29: 1317-31.
25. Mattson MP, Gary DS, Chan SL, Duan W. Perturbed endoplasmic reticulum function, synaptic apoptosis and the patogenesis of Alzheimer's disease. Biochem Soc Symp 2001;67:151-62.
26. Paschen W, Frandsen A. Endoplasmic reticulum dysfunction-a common denominador for cell injury in acute and degenerative diseases of the brain? J Neurochem 2001;79:719-25.
27. López MF, Kristal BS, Chernokalskaya E, Lazarev A, Shestopalov AI, Bogdanova A, et al. Hightroughput profiling of the mitocondrial proteome using affinity fractionation and automation. Electrophoresis 2000;21:3427-40.
28. Taupin P, Ray J, Fischer WH, Suhr ST, Hakansson K, Grubb A et al. FGF-2 responsive neural stem cell proliferation requires CCg, a novel autocrine/paracrine cofactor. Neuron 2000;28:385-97.
29. Bergquist J, Tarkowski A, Swing A, Ekman R. Catecholaminergic suppression of immunocompetent cells. Immunol Today 1998; 19:562-7.
30. Skold K, Svensson M, Kaplan A, Bjorkesten L, Astrom J, Andren PE. A neuroproteomic approach to targeting neuropeptides in the brain. Proteomics 2002;2:447-54.
31. Svensson M, Skold K, Svenningsson P, Andren PE. Peptidomics-based discovery of novel neuropeptides. J Proteome Res 2003; 2:213-9.
32. Naslund J, Schierhorn A, Hellman U, Lannfelt L, Roses AD, Tjernberg LO, et al. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci USA 1994;91:8378-82.
33. Adkins JN, Varnum SM, Auberry KJ, Moore RJ, Angell NH, Smith RD, et al. Toward a human blood serum proteome analysis by multi-dimensional separation coupled with mass spectrometry. Mol Cell Proteomics 2002;1:947-55.
34. Sironi L, Tremoli E, Miller I, Guerrini U, Calvio AM, Eberini I. Acute-Phase Proteins Before Cerebral Ischemia in Stroke-Prone Rats: identification by proteomics. Stroke 2001;32:753-60.
35. Fornage M, Swank MW, Boerwinkle E, Doris PA. Gene expression profiling and functional proteomic analysis reveal perturbed kinase-mediated signaling in genetic stroke susceptibility. Physiol Genomics 2003;15:75-83.
36. Dhodda VK, Sailor KA, Bowen KK, Vemuganti R. Putative endogenous mediators of preconditioning-induced ischemic tolerance in rat brain identified by genomic and proteomic analysis. J Neurochem 2004;89:73-89.
37. Hinerfeld D, Traini MD, Weinberger RP, Cochran B, Doctrow SR, Harry J, et al. Endogenous mitochondrial oxidative stress neurodegeneration proteomic analysis, specific respiratory chain defects, and efficacious antioxidant therapy in superoxide dismutase 2 null mice. J Neurochem 2004;88:657-67.
38. Lescuyer P, Allard L, Zimmermann-Ivol CG, Burgess JA, Hughes-Frutiger S, Burkhard PR, et al. Identification of post-mortem cerebrospinal fluid proteins as potential biomarkers of ischemia and neurodegeneration. Proteomics 2004;4:2234-41.
39. Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 1995;45:1092-6.
40. Merched A, Xia Y, Visvikis S, Serot JM, Siest G. Decreased high-density lipoprotein cholesterol and serum apolipoprotein Al concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol Aging 2000;21:27-30.
41. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 2000;7:321-31.
42. Butterfield DA, Kanski J. Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer's amyloid beta-peptide 1-42. Peptides 2002;23:1299-309.
43. Kanski J, Aksenova M, Butterfield DA. The hydrophobic environment of Met35 of Alzheimer's Abeta(1-42) is important for the neurotoxic and oxidative properties of the peptide. Neurotox Res 2002;4:219-23.
44. Smith MA, Richey PL, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 1997;17:2653-7.
45. Castegna A, Thongboonkerd V, Klein J, Lynn BC, Wang YI, Osaka H, et al. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem 2003;85:1394-401.
46. Choi J, Malakowsky CA, Talent JM, Conrad CC, Gracy RW. Identification of oxidized plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun 2002;293:1566-70.
47. Olanov CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 1999;22:123-44.
48. Basso M, Giraudo S, Corpillo D, Bergamasco B, Lopiano L, Fasano M. Proteome analysis fo human substantia nigra in Parkinson's disease. Proteomics 2004;4:3943-52.
49. Hirsch EC, Hoglinger G, Rousselet E, Breidert T, Parain K, Feger J, et al. Animal models of Parkinson's disease in rodents induced by toxins: an update. J Neural Transm Suppl 2003;65:89-100.
50. De Iuliis A, Grigoletto J, Recchia A, Giusti P, Arslan P. A proteomic approach in the study of an animal model of Parkinson's disease. Clin Chim Acta 2005;357:202-9.
51. Jin J, Meredith GE, Chen L, Zhou Y, Xu J, Shie FS, et al. Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson's disease. Mol Brain Res 2005;134:119-38.
52. Fukada K, Zhang F, Vien A, Cashman NR, Zhu H. Mitochondrial Proteomic Analysis of a cell line model of familial amyotrophic lateral sclerosis. Mol Cel Proteomics 2004;3: 1211-23.
53. Ranganathan S, Williams E, Ganchev P, Gopalakrishnan V, Lacomis D, Urbinelli L, et al. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem 2005;95:1461-71.
54. Pasinetti G, Ungar L, Lange D, Yemul S, Deng H, Yuan X, et al. Identification of potential CSF biomarkers in ALS. Neurology 2006;66:1218-22.
55. Perluigi M, Poon FH, Maragos W, Pierce WM, Klein JB, Calabrese V, et al. Proteomic analysis for protein expresion and oxidative modification in R6/2 transgenic mice. Mol Cell Proteomics 2005;4:1849-61.
56. Meisler MH, Kearney J, Ottman R, Escayg A. Identification of epilepsy genes in human and mouse. Annu Rev Genet 2001;35:567-88.
57. Park SA, Kim TS, Choi KS, Park HJ, Heo K, Lee BI. Chronic activation of CREB and p90RSK in human epileptic hippocampus. Exp Mol Med 2003;35:365-70.